We’re thrilled to announce that Novartis, a proudly Swiss company, is an Official Partner of the Eurovision Song Contest 2025, hosted in our headquarters city of #Basel, #Switzerland. Like Novartis, the Eurovision Song Contest was founded in Switzerland, and we’re delighted to offer our support to this legendary contest and our home country. For ten unforgettable days, Basel will transform into a global hub of creativity and community, bringing together millions of viewers from across the world and thousands of visitors to Basel. With 78,000 employees from over 100 countries, at Novartis, we believe in the power of collective creativity and international collaboration — values we share with Eurovision. So, here’s to seizing the moment and meeting at the intersection of science and creativity! Stay tuned for more news on our involvement. Novartis, where health takes center stage. #EurovisionBasel #novartislife #HealthCentreStage #ESC2025 #Eurovision #Eurovision2025 European Broadcasting Union (EBU) SRG SSR
Info
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
Externer Link zu Novartis
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel, Baselstadt
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand und Gene and cell therapy
Orte
Beschäftigte von Novartis
-
Guy Dickinson
Figuring out #FutureOfWork: GenerativeAi + Employee Experience + Behavioural Design + Capability Building + Digital Skills
-
David Yee
Head Portfolio Systems, Portfolio Strategy & Analytics, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
Updates
-
This FDA approval for adults with newly diagnosed chronic myeloid leukemia (#CML) is vital for the clinical and patient communities. As a part of our 20+-year commitment to innovation and support in CML, we continue to work alongside the clinical and patient communities. #ReimaginingMedicine
We are proud to announce the FDA approval for adults with newly diagnosed Ph+ chronic myeloid leukemia (#CML) in chronic phase. About 10,000 people each year are diagnosed with chronic myeloid leukemia in the US. With this approval, up to 4 times the number of currently eligible patients will have the opportunity to explore a new treatment. #NovartisNews #ReimaginingMedicine
-
Our Q3 performance reflects the strong operational performance and key pipeline milestones this quarter. With continued strong business momentum in our business and pipeline, we were able to once again upgrade our full-year guidance. We remain highly confident in our mid-term outlook. https://lnkd.in/gT6qWxsx #NVSQ324
-
-
Novartis hat dies direkt geteilt
Executive Vice President, Chief Commercial Officer, Novartis US | Corporate Board Director
At Novartis, we have the scale, expertise and capabilities to help turn molecules into medicines into patient outcomes. In addition to research from our own labs, we are always looking for opportunities to join forces with biotech companies to ensure that the most promising innovation has the best chance of reaching patients. I recently joined Michelle Benz for a fireside chat at the Fierce Biotech Summit where we discussed our creative approach to partnerships which has led to successful collaborations to advance patient care. We talked a lot about making decisions with our heads (understanding where mutual value is created), hearts (doing what’s right for patients) and hands (doing our best to get cutting-edge science to market). When the head, heart and hands are there, everyone wins! Get in touch to reimagine medicine, together: https://lnkd.in/eJgaDR8W
-
-
Millions of people around the world face barriers to accessing quality healthcare. Women face the additional challenge of being underdiagnosed for certain conditions - like cardiovascular disease - compared to men. Our Chief Legal Officer, Karen Hale, joined a panel of distinguished women in business at the Fortune Most Powerful Women summit to discuss the pressing health inequities in our society, presenting both challenges and opportunities for rethinking healthcare. View the panel discussion here: go.novartis.social/409rskr At Novartis, our access and equity work is about more than medicine; it's about extending and improving lives. Learn more https://lnkd.in/gt8RxuJP #HealthEquity #FortuneMPW #ReimaginingMedicineTogether #PartnershipForChange
-
-
As #BreastCancerAwarenessMonth continues, we’re spotlighting EUROPA DONNA - The European Breast Cancer Coalition Breast Health Day campaign encouraging people of all ages to understand the importance of breast cancer prevention. We are honored to join the community in driving these important conversations and continue raising awareness of breast cancer and its impact. #BCAM
🌸 It's Breast Health Day! 🌸 On this 15th of October, Europa Donna encourages women of all ages to take steps towards breast cancer prevention and understand the importance of early detection ✨ Here are some tips to keep your breast health in check: 🍎 Eat a balanced diet rich in fruits and vegetables. 💃 Stay active – regular exercise supports a healthy lifestyle. 🤸♀️ Limit alcohol and avoid smoking. 🔍 Don’t forget regular check-ups – early detection saves lives. Start a healthier life TODAY. Make every choice count 💗 🔗 https://bit.ly/4dIGKzT Illustrations by Libby VanderPloeg Animation by Gary Dumbill #BreastHealthDay #EuropaDonna #BreastCancerAwareness #Prevention #HealthyLiving #BHD
-
Novartis announces positive CHMP opinion for adults diagnosed with stage II or III HR+/HER2- #EarlyBreastCancer, who face high risk of recurrence, including those with node-negative disease. People diagnosed with this type of early breast cancer face the reality that their cancer could come back in the long term, often as incurable, metastatic disease. People with breast cancer deserve more treatment options that might have a tangible impact on their lives and make a meaningful difference in their journey. This milestone means adults living with stage II or III HR+/HER2- early breast cancer in Europe are now one step closer to having a new option that could help them take back control and reduce their risk of recurrence. #ReimaginingMedicine
-
Every year, over 2 million people are diagnosed with #BreastCancer globally. This #BreastCancerAwarenessMonth, we are excited to spotlight the incredible work of Rethink Breast Cancer to empower and support those affected by this disease. We are proud to stand alongside the community and support their efforts in raising awareness of breast cancer and its impact. Join the conversation and learn more about breast cancer. Every share, every voice, and every action make a difference. #BCAM
YOU DESERVE TO BE COUNTED. #MAKEMECOUNT Breast cancer awareness month is here. Every October, the media cycle and public focus shifts ever so briefly to our cause and that can bring on a mix of emotions for our community, our team sure feels it, myself, too. “Yay” that we are being seen and talked about. But “ouch” when the story is full of gaps. And that’s a big part of why we launched #MakeMeCount today. That juxtaposition between the general public’s perceptions of breast cancer and the reality of the community’s experiences can be quite jarring and exposes the gaps. The dominant breast cancer story has a lot of gaps because our cancer data has gaps. It’s incomplete. It’s reported on at too high a level. We don’t know how many Black women are diagnosed in Canada. We don’t know how Indigenous communities are impacted. We don’t have data on outcomes for sexual and gender diverse groups. We don’t know how disabilities or income play a role in someone’s care. Vesna is someone who had a metastatic recurrence and she, too, is not counted. Only her first early-stage breast cancer diagnosis is captured in the stats. Her past 7.5 years of MBC treatment aren’t captured. Watch her video below. We can guess at who is having worse outcomes and why, but guessing isn’t good enough. Rethink wants more human dimensions to be counted in the data. Because you count when you’re counted. With #MakeMeCount, we are calling out the need for improved reporting on metastatic recurrence data, race-based data, and social determinants of health data within the breast cancer community. Head to the 🔗 below to sign our petition today and watch the videos of our “stat stars” to learn more about the real people who are impacted by these gaps. For more on why this campaign matters, our history of working on these issues and what actions we’re taking, MJ, Rethink’s Founder + Executive Director has written a blog, which you can read via the 🔗 below too. 👉 https://lnkd.in/eQSPXhK3 Thank you for your support in using your voice to help close these gaps. 💗 #MakeMeCount 🏷️ #breastcancer #breastcancercommunity #metastaticbreastcancer #mbc #cancerdata #breastcancerawarenessmonth #breastcancercharity #cancercharity #canceradvocate #canceradvocacy #breastcanceradvocacy #rethinkbreastcancer
-
Novartis hat dies direkt geteilt
Huge news today that recognizes the role AI is already playing in reimagining medicine. Novartis is proud to work alongside Demis and the team at Isomorphic Labs to accelerate our drug discovery efforts and create new therapies to treat a range of diseases. Alphafold is already transforming the ways we find new medicines and accelerating our research efforts. We’re just beginning to realize the potential of this technology, but the impact will only grow over time. On behalf of all of us, congratulations to Demis Hassabis, John Jumper, and David Baker on the recognition of their historic work.
-
“I am the only one who can take care of myself and as a leader it is my duty to role-model and show others we are the creators of our schedules, our decisions and ultimately our wellbeing”. Meet Nejc Jaka Sekula, our Global Head Talent Diversity, Equity and Inclusion. Motivated by his recent physical health challenges and the impact on his mental health and wellbeing, he is now putting into place small practices that help himself and his team prioritize self-care and create a safe space for them to be their authentic selves. By choosing one small step to improve our mental health and wellbeing, we care to thrive together. #NovartisTogether #MentalHealth #ThriveTogether
Verbundene Seiten
Ähnliche Seiten
Aktien
NVS
NYSE
Verzögerung von 20 Minuten
106,45 $
-0,63 (-0,588 %)
- Aktiv
- 106,61
- Niedrig
- 106,13
- Hoch
- 106,69
Daten von Refinitiv
Mehr Informationen aufFinanzierung
Novartis
Insgesamt 2 Finanzierungsrunden
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.487.694.394,00 $